On April 11, 2016, the FDA approved venetoclax for use in those with CLL who have 17p deletion (deletion located on the chromosome 17 short arm) and who have been treated with at least one prior therapy [REF].
In October 2016 a European Medicines Agency committee recommended provisional marketing approval for venetoclax for CLL; the drug had already been granted orphan status in 2012 for that use [REF].